Veracyte Meets New Medicare Coverage Mandate For Molecular Dx
This article was originally published in The Pink Sheet Daily
Veracyte announced a positive coverage policy from Palmetto GBA Jan. 9 for its Afirma multi-gene expression classifier test, one of the first to go through the Medicare contractor’s new requirements.
You may also be interested in...
Recent moves by CMS have left up in the air an innovative program that gives labs a clearer opportunity to demonstrate clinical utility and test value. It’s therefore unclear whether companies and their backers should expect any greater certainty over the ability to command premium prices for high-value diagnostic tests.
The Medicare contractor that handles claims for California and several other states is taking steps to enhance its control over reimbursement of molecular diagnostic tests.
Specific reimbursement codes have been developed for the first time for more than 100 genetic tests, but they will not be adopted by Medicare until at least 2013 as CMS figures out how to incorporate them into the payment system.